{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "Liu_et_al.__2024_",
  "verification_stats": {
    "total_extracted": 2,
    "verified": 0,
    "rejected": 2,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": "comp_1",
      "quote": "For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody in the 45\u221264 years group, it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A).",
      "reason": "does not support claim",
      "original_explanation": "This quote directly supports the claim that Flublok (RIV4) is linked to greater immunogenicity compared to standard-dose flu vaccines, specifically by showing a significant increase in total HA head binding antibodies after RIV4 vaccination."
    },
    {
      "id": "comp_2",
      "quote": "In year 2, among the 7 repeat vaccination arms (IIV4-IIV4, IIV4-ccIIV4, IIV4-RIV4, RIV4-ccIIV4, RIV4-RIV4, ccIIV4-ccIIV4 and ccIIV4-RIV4), repeat vaccination with either RIV4 or ccIIV4 further improved antibody responses to circulating viruses compared to IIV4.",
      "reason": "does not support claim",
      "original_explanation": "This quote provides evidence that RIV4 (Flublok) is associated with greater immunogenicity than standard-dose IIV4, as repeat vaccination with RIV4 led to improved antibody responses."
    }
  ],
  "model_used": "gpt-4.1"
}